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incompatibility caused by conventionally manufactured PD3,4-Dideoxyglucosone-3-ene (3,4-DGE): A cytotoxic glucose
fluids.degradation product in fluids for peritoneal dialysis.
Background. Bioincompatible glucose degradation prod-
ucts (GDPs) in fluids for peritoneal dialysis (PD) develop dur-
ing sterilization and storage. Their biological activity has suc-
In 1887 E´mile Roux, working in Pasteur’s laboratorycessfully been monitored through the use of various in vitro
in Paris, published a report revealing that sugar solutionsmethods but their molecular and chemical nature is less well
understood. Many GDPs are highly reactive carbonyl com- became toxic toward bacteria just by being exposed to
pounds. Although some of the identified GDPs are extremely sunlight [1]. Degradation products from the sugars were
cytotoxic, none of them actually possess cytotoxicity at the pointed out as the cause of the toxicity. On the molecularconcentrations found in PD fluids. Thus, the GDP responsible
level, the reason for the toxicity is still not understood.for the toxicity in PD fluids has not yet been identified. The
Glucose is extensively used in medical fluids. In 1991intention of the present work was to investigate to what extent
the unsaturated dicarbonyl compound, 3,4-dideoxyglucosone- it was shown that heat sterilized fluids for peritoneal
3-ene (3,4-DGE) was present in PD fluids, and if it could be dialysis (PD fluids), in contrast to filter-sterilized fluids,
responsible for the in vitro effects on L-929 fibroblast cells.
caused severe inhibition of cell growth (ICG) of L-929Methods. A commercial preparation of 3,4-DGE and two
fibroblasts [2]. Glucose degradation products (GDPs)different liquid chromatography methods were used for the
chemical identification and quantification. In vitro bioincom- formed during heat sterilization were found to be respon-
patibility was determined as inhibition of cell growth using the sible for the cytotoxicity. Later, the toxicity due to GDPs
L-929 fibroblast cell line. was confirmed using several other cell-based systems
Results. 3,4-DGE was present in conventionally manufac-
including mesothelial cells. Animal models and clinicaltured PD fluids at a concentration of 9 to 22 mol/L. In the
studies also confirmed the bioincompatibility of GDPsnewly developed PD fluid, Gambrosol trio, the concentrations
were 0.3 to 0.7 mol/L. When added as synthetic 3,4-DGE to [3–10].
cell growth media at the concentrations measured in conven- Glucose degradation products are known to be strong
tional PD fluids, the inhibition of cell growth was significantly precursors of advanced glycosylation end products (AGE)lower than for that seen with the conventional fluids. However,
[11–13]. As some GDPs are transported across the peri-in the conventional PD fluids the total amount of 3,4-DGE
toneal membrane and appear in the blood, they mightavailable for toxic reactions most probably was higher than
that measured, because 3,4-DGE was freshly recruited from a not only have local effects on the peritoneal membrane
molecular pool when consumed. The speed of this recruitment but may also add to the systemic carbonyl stress [14–16].
was high enough to explain most of the growth inhibition seen Removal or reduction of the GDP concentrations in PDfor heat-sterilized PD fluids.
fluids through new manufacturing processes in clinicalConclusion. 3,4-DGE is present in conventional PD fluids
trials has been demonstrated to have a clear-cut benefi-at a concentration between 9 and 22 mol/L, and is the most
biologically active of all GDPs identified to date. Thus, it is cial impact on the peritoneal membrane during PD.
the main candidate to be held responsible for the clinical bio- Thus, all biological data related to the effects of GDPs
indicate that simple cell lines (such as L929) constitute
a rapid first screening system with a high predictive valueKey words: biocompatibility, peritoneal dialysis, dialysate, 3,4-DGE,
toxicity, glucose. for human bioincompatibility of PD fluids.
The possible theoretical number of GDPs is very large,
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be practical. Some GDPs such as acetaldehyde, 3-deox- 2002 by the International Society of Nephrology
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Fig. 1. Glucose degradation, a comprehensive scheme for mildly acidic conditions such as in peritoneal dialysis (PD) fluids. Fragmentation reactions
on enols and dicarbonyl compounds produce low molecular aldehydes and carboxylic acids. Also, recombination of fragments and intermediates
could occur. The number of possible degradation products is probably very high.
yglucosone (3-DG), formaldehyde, 2-furaldehyde, gly- stance from seaweed and demonstrated toxic and immu-
nosuppressive effects on various cell systems [20].oxal, 5-hydroxymethylfurfurale (5-HMF), and meth-
ylglyoxal have been chemically identified and quantified In general, unsaturated dicarbonyl compounds are
known to be much more toxic than the correspondingin PD fluids [4, 11]. However, none of these compounds
showed cytotoxicity in the L-929 system, either alone or saturated dicarbonyls of the same backbone structure
[21]. As 3,4-DGE is reported to be a possible degradationin mixtures at the concentrations found in PD fluids
product from carbohydrates and, as it is suspected to be[5, 7]. Thus, the GDP(s) responsible for the cytotoxicity
a rather toxic unsaturated carbonyl with high reactivity,could not be identified.
it possesses all the characteristics required to make it aA recent study demonstrates that known GDPs in
candidate for the cytotoxicity of conventionally manufac-concentrations relevant for PD fluids do impair viability
tured PD fluids. The aim of this study was to identifyand function of mesothelial cells in an in vitro model
and quantify 3,4-DGE in different PD fluids and to inves-[17]. The effect was revealed through the use of very
tigate if 3,4-DGE could be the substance responsible forlong incubation times, up to 36 days. PD fluids were not
the cytotoxicity reported for heat-sterilized PD fluids.included in the study, and thus the question of whether
any of the GDPs tested is the main one responsible
for the cytotoxicity of heat-sterilized PD fluids was not
METHODS
addressed.
Identification and quantificationOur interest recently has focused on 3,4-dideoxygluco-
sone-3-ene (3,4-DGE), an intermediate in the degrada- 3,4-Dideoxyglucosone-3-ene was identified using a com-
mercial preparation (Toronto Research Chemicals, To-tion of glucose to 5-HMF (Fig. 1). During the sixties,
Anet synthesized and described 3,4-DGE along with ronto, Canada) and a liquid chromatography (LC) sys-
tem (model 1100; Hewlett Packard, Palo Alto, CA,other unsaturated glucosones in a series of articles on
mechanisms for glucose degradation and the Maillard USA) equipped with a diode array detector (DAD). Our
current study describes two different LC methods forreaction [18, 19]. No toxicity data on 3,4-DGE were
available until 1994, when Kato et al isolated the sub- the determination of 3,4-DGE, one using reversed phase
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(RP) chromatography on a C18 column and one using an 72 hours of incubation as previously described [3, 5].
Concentration response curves were obtained by addingion exchange column, both with diode array detection.
According to Anet [18] the cis form of 3,4-DGE has different concentrations of 3,4-DGE from a freshly
thawed stock solution to cell growth media. PD-fluidsan absorption maximum at 228 nm. This was used for
identification since this absorbance characteristic is typi- were tested after dilution with cell growth media supple-
mented with 10% fetal calf serum. The dilution was (5cal of -unsaturated dicarbonyl compounds. The mo-
lecular mass 144 expected for 3,4-DGE for the commer- 6) for the 1.5% fluid and (4  7) for the 4% fluid.
cial preparation was confirmed using a mass detector
Equilibrium experimentsequipped with an electrospray interface (Bruker Dalton-
ics, Bremen, Germany). The nebulizer was held at 4000 V 3,4-Dideoxyglucosone-3-ene GE was removed from
conventional PD fluids (Gambrosol) using ENV solidwith an end plate offset of 500 V. Nitrogen was used as
a dry gas (30 L/min, 250C) and as a nebulizing gas (7 psi). phase extraction columns (International Sorbent Tech-
nology, Mid Glamorgan, UK). These columns are madeThe mass spectrometer was set to scan between 50 and
200 m/z. of polystyrene-divinyl-benzene polymer and are de-
signed for removal of unsaturated polar substances. Con-
Separation columns used ventional PD-fluids (Gambrosol), conventional PD fluid
from which 3,4-DGE had been removed, and sterile fil-Reversed phase. For the reversed phase, a Supelcosil
C18 column (Supelco, Bellefonte, PA, USA) eluted with tered PD fluid were all kept at room temperature (22C)
and were then incubated at 37C for three days. 3,4-DGEa gradient consisting of methanol-water was used. The
flow rate was 1 mL/min, the gradient started with six was determined on days 1, 2 and 3 of the incubation.
minutes of 5% methanol and 95% water; from six to ten
minutes the methanol content was linearly increased to
RESULTS
100%, held there for six minutes and then returned to
Identification5% over a period of two minutes, where it was held for
another two minutes prior to the next injection. Injection Chromatograms obtained either with the Supelcosil
C18 column (Fig. 2A) or the Aminex 87-H columns re-volume was 20 L and the DAD detector was set to 230
nm. Samples were injected at 4C with a refrigerated vealed one main and one minor peak caused by the
commercial 3,4-DGE preparation. Both peaks had a UV-autosampler.
Ion exchange. Two Bio-Rad Aminex 87-H columns absorption maximum at 228 nm. The UV-absorption
spectrum for the main peak for the Supelcosil C18 column(Bio-Rad Laboratories, Hercules, CA, USA) coupled in
series and eluted with 5 mmol/L H2SO4 with a flow rate is presented in Figure 2B. The chromatographic peaks
had the same retention time and spectrum for the com-of 0.5 mL/min were used. Injection volume was 20 L
and the DAD detector was set at 230 nm. Sample injec- mercial 3,4-DGE as for PD-fluids. The mass number 144
for 3,4-DGE was confirmed using mass spectrometry.tion was the same as for the reversed phase.
Since the relative heights of the chromatographic peaks
Fluids were approximately the same for PD-fluids (Fig. 2C) and
commercial 3,4-DGE (Fig. 2A), only the main peak wasLaboratory-made sterile-filtered PD-fluid, conventional
PD-fluid (Gambrosol; Gambro AB, Lund, Sweden) and used for quantification.
a newly developed PD-fluid produced in a three com-
Quantificationpartment bag using low pH in the glucose compartments
(Gambrosol trio) were investigated in this study. Using a standard curve prepared from commercial 3,4-
DGE (dissolved in sterile-filtered PD fluid), the concen-
Standard curve tration of 3,4-DGE in one bag of conventional 4% PD
fluid was found to be 22  1 mol/L with the SupelcosilA 3,4-DGE standard curve was prepared, using the
commercial preparation, in sterile-filtered PD fluid. The C18 column and 19  1 mol/L with the Aminex 87-H
columns (mean  SEM, N  3). Samples from one bagcontent of 3,4-DGE in different PD fluids was then deter-
mined by measuring the height of the peaks correspond- were injected into the high-pressure liquid chromatogra-
phy (HPLC) in triplicate. In the Aminex 87-H columning to those of the 3,4-DGE standard and the concentra-
tion calculated assuming a linear relation between peak diluted acid was used as eluent. According to Kato et
al, there could be a risk of instability at low pH for 3,4-height and concentration.
DGE [20]. Further quantification thus was performed
In vitro assay of cytotoxicity with the L-929 method using only the Supelcosil C18 column with an ordinary
UV-detector, which showed comparable results to thoseInhibition of cell growth (ICG) was determined on
mouse fibroblast cells L-929 (CCL-1; ATCC, Rockville, obtained with the DAD detector. Using this method the
content of 3,4-DGE in sterile filtered fluid, GambrosolMD, USA) using the neutral red vital stain assay after
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Fig. 2. Chromatogram of a commercial 3,4
dideoxyglucosone-3-ene (3,4-DGE; A), ultra-
violet-diode array detector (UV-DAD) spec-
trum of the main peak of a commercial 3,4-
DGE (B), and a chromatogram of Gambrosol
4% PD fluid (C). The analysis method used
a Supelcosil C18 column. The peak at 10.7 min-
utes corresponds to 5-hydroxymethylfurfurale
(5-HMF).
and Gambrosol trio was analyzed in different bags from lated 3,4-DGE concentrations in the growth media/PD-
fluid mixtures were thus 4.5 and 8 mol/L, respectively.different production batches (Table 1).
Concentration response curveCytotoxicity
The results from incubating L-929 cells with commer-Conventional PD fluids (Gambrosol; 1.5 and 4% glu-
cial 3,4-DGE added to the cell growth media are pre-
cose, containing 9.9 and 22 mol/L 3,4-DGE) resulted in sented in Figure 3. EC50, that is, a 50% reduction in
21 4 and 27 4% (mean SEM, N 6), respectively, growth, was observed for a concentration of 32  2
higher inhibition of cell growth (ICG) than the corre- mol/L 3,4-DGE. According to the concentration re-
sponding sterile-filtered PD fluids. At testing, the 1.5 and sponse curve the 3,4-DGE concentrations found in 1.5
4% PD fluids were added to cell growth media in the and 4% PD fluids would cause about a 5 and 10% ICG,
respectively, as the PD fluids were tested diluted withproportions (56) and (47), respectively. The calcu-
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Table 1. Concentration of 3,4-dideoxyglucosone-3 in bags of
different peritoneal dialysis fluids
Type of PD fluid 1.5% 2.5% 4%
Sterile filtered 0.07 0.07 0.07
Gambrosol 9.10.6 13.31.0 18.31.1
Gambrosol trio 0.30.0 0.40.0 0.70.1
Data are meanSEM, N  3.
growth media (Fig. 3). This was substantially lower than
the 21 and 27% ICG measured for the actual PD fluids.
Fig. 3. Concentration response curve for 3,4-DGE in cell growth me-
dium. The response measured as inhibition of cell growth (ICG) with3,4-DGE equilibrium
L-929 fibroblasts. Data are mean  SEM, N  6.
Figure 4 demonstrates that when a conventional 1.5%
PD fluid that has been stored at 22C was incubated
at 37C for three days, the concentration of 3,4-DGE
two independent chromatographic methods with diodeincreased from 10 mol/L to 16 mol/L. When 3,4-DGE
array detection and confirmation with mass spectrome-was removed from a PD fluid using an ENV solid-phase
try. The results strongly suggest the presence of 3,4-DGEextraction column, 12 mol/L new 3,4-DGE was formed
as a GDP in peritoneal dialysis fluids. In agreement withwithin three days during the 37C incubation. When 10
the commercial suppliers’ findings using thin layer chro-
mol/L of 3,4-DGE was added to sterile-filtered 1.5%
matography and NMR, we found that 3,4-DGE most
PD fluid initially containing no 3,4-DGE, the concentra- probably exists in different isomeric forms. In addition
tion decreased to 5 mol/L after three days at 37C. to the main cis isomer, a possible minor cis isomer was
There were no concomitant alterations in the 5-HMF seen as a second peak in the chromatograms. These
concentrations. peaks could be detected both in synthetic standard solu-
tions and in PD fluids.
Synthetic 3,4-DGE earlier was qualitatively identified
DISCUSSION with thin layer chromatography, NMR and UV spectra
3,4-Dideoxyglucosone-3-ene represents a novel GDP [18–20]. Quantification in degraded sugar solutions or
and this study demonstrates the identification and quan- other complex matrices has not been performed to our
knowledge.tification of 3,4-DGE in different PD fluids. Among the
According to Anet, 3,4-DGE has an absorption maxi-GDPs identified in PD fluids, 3,4-DGE is the only one
mum at 228 nm [18]. It is thus one of the few GDPs thatcausing cytotoxicity in the L-929 in vitro system used at
absorb UV-light at 228 nm (5-HMF is another). It hasthe concentrations found in PD fluids. The concentra-
been proposed that the toxicity in PD fluids under certaintions of other GDPs tested have to be at least three
circumstances is related to the absorbance at 228 nmtimes, and in most cases more than ten times, higher
[25]. Our findings indicate that 3,4-DGE is the mainthan those actually found in the PD fluids in order to
GDP causing UV absorbance at 228 nm and is thusinduce ICG [5, 7].
indirectly related to the cytotoxicity of PD fluids.In the present study we chose to use inhibition of cell
When increasing the temperature of a PD fluid fromgrowth of an in vitro cultured mouse fibroblast cell line
room temperature to 37C, during a three-day incuba-
(L-929) as the endpoint for the cytotoxicity. This method
tion, the concentration of 3,4-DGE increases signifi-
represents an internationally well proven, well-charac- cantly. After solid phase extraction 3,4-DGE is regener-
terized, and reproducible in vitro system, often used as ated already after two days of incubation. Thus, as the
the first line screening for basal cytotoxicity. It was used cellular exposure is performed at 37C, we speculate that
in our first article describing biological side effects re- 3,4-DGE is consumed by the presence of the cells and
lated to GDPs in PD fluids [2], and its use in the develop- that new 3,4-DGE may be recruited during the test.
ment of a new PD fluid (Gambrosol trio) has resulted Therefore, the actual amount of 3,4-DGE available in
in considerably fewer bioincompatible reactions when the incubation mixture (PD fluid/medium) may be at
applied to patients [22–24]. Using this method as a probe least twice as high as that suggested by the measured
3,4-DGE turns out to be by far the most biologically concentration. If so, the total content of 3,4-DGE in
active of the hitherto identified GDPs. conventional PD fluids is high enough to explain virtually
all of the observed in vitro cytotoxicity.The identification of 3,4-DGE was performed using
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Fig. 4. Concentration of 3,4-DGE in 1.5% PD fluids during a three day incubation at 37C. Data are mean  SEM, N  3. (A) Conventional
PD fluid. (B) Conventional PD fluid extracted with an ENV column. (C) Sterile-filtered PD fluid supplemented with 10 mol/L 3,4-DGE.
3,4-Dideoxyglucosone-3-ene GE was first isolated Advanced glycation end products represent a large
variety of biological activities [26–29] and are suggestedfrom the water extract of a kind of brown seaweed,
Yendo, which is known to possess immunosuppressive to participate in the remodeling of the peritoneal mem-
brane leading to changes of transport characteristics. 3,4-effects. Thus, the investigation concerning biological ef-
fects related to 3,4-DGE was first of all focused on the DGE has been discussed as being an intermediate in the
Maillard reaction [30, 31] and thus a promoter of AGEimmune system. It was reported that 3,4-DGE sup-
pressed thymocyte proliferation (EC50  1.2 mol/L), formation. However, it remains to be elucidated whether
the concentrations of 3,4-DGE in conventional PD fluidssuppressed interleukin-1 (IL-1) production from lipo-
polysaccharide (LPS)-stimulated peritoneal macrophages is high enough to explain the AGE formation.
(EC50  3.7 mol/L) and suppressed LPS-induced anti- In conclusion, 3,4-DGE has been identified and quan-
body production from spleen cells (EC50 around 3,5 tified as a novel GDP in conventional heat-sterilized PD
mol/L). However, 3,4-DGE at these concentrations was fluids. It has also been demonstrated to be the most
reported to have very little or no effect on growth of biologically active GDP identified to date, and thus a
bone marrow cells, L-929 cells or melanoma cells [20]. key substance for determining biocompatibility of PD
These findings suggest that 3,4-DGE more selectively fluids. By using new manufacturing procedures 3,4-DGE
suppresses immune cells/functions than the proliferation formation in fluids for PD may be almost totally avoided.
of tumor cells. The comparatively high EC50 value of
32 mol/L further indicates that the L-929 proliferation ACKNOWLEDGMENTS
assay used in our study does not exaggerate the biological This study was financed by Gambro AB, Lund, Sweden and partly
effects related to 3,4-DGE, but instead most probably by a grant from the Swedish Technical Research Counsel. The authors
are grateful to Ms. Randi Ipsen for linguistic advice. Parts of this workunderestimates the effects.
were presented as a poster at ASN/ISN World Congress of Nephrology,In vivo, 3,4-DGE has been reported to have a sup- 2001, San Fransisco, CA, USA.
pressive effect in experimental mouse disease models for
Reprint requests to Torbjo¨rn Linde´n, Ph.D., Gambro AB, Box 10101,the delayed-type hypersensitivity reaction (cell-medi-
S-220 10 Lund, Sweden.ated immune response) as well as a dose dependent
E-mail torbjorn.linden@gambro.com
effect on collagen induced arthritis [20].
In peritoneal dialysis, GDPs have been suggested to be REFERENCES
the cause of peritonitis and ultrafiltration failure [9, 23].
1. Roux PA: De l’action de la lumie`re et de l’air. Annales PasteurRecent multicenter clinical studies have shown that the
1:445–452, 1887
use of PD fluids with very low levels of GDPs can result 2. Wieslander A, Nordin M, Kjellstrand P, Boberg U: Toxicity
of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidneyin a significant change of several dialysate markers of
Int 40:77–79, 1991peritoneal integrity, indicating a better preserved mem-
3. Wieslander AP, Forsba¨ck G, Svensson E, Linden T: Cytotoxic-
brane [22–24]. Thus, as 3,4-DGE is cytotoxic and sup- ity, pH and glucose degradation products in four different PD-
fluids. Adv Perit Dial 12:57–60, 1996presses immune reactions, it might be the link between
4. Nilsson-Thorell CB, Muscalu N, Andren AHG, et al: Heatreported clinical drawbacks and PD fluid composition,
sterilization of fluids for peritoneal dialysis gives rise to aldehydes.
and thus the key substance for determining bioincompat- Perit Dial 13:208–213, 1993
5. Wieslander A, Andre´n A, Nilsson-Thorell C, et al: Are alde-ibility.
Linden et al: Bioincompatibility and 3,4-DGE 703
hydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? 17. Witowski J, Wisniewska J, Korybalska K, et al: Prolonged expo-
sure to glucose degradation products impairs viability and functionPerit Dial Int 15:348–352, 1995
6. Breborowicz A, Oreopoulos G: In vitro studies to assess biocom- of human peritoneal mesothelial cells. J Am Soc Nephrol 12:2434–
2441, 2001patibility of peritoneal dialysis solutions: Strengths and limitations.
Perit Dial Int 16:119–123, 1996 18. Anet EFLJ: Degradation of carbohydrates, III: Unsaturated hexo-
sones. Aust J Chem 15:503–509, 19627. Witowski J, Korybalska K, Wisniewska J, et al: Effect of glucose
degradation products on human mesothelial cell function. J Am 19. Anet EFL: 3-deoxyglycosuloses (3-Deoxyglycosones) and the deg-
radation of carbohydrates. Adv Carbohydr Chem 19:181–218, 1964Soc Nephrol 11:729–739, 2000
8. Musi B, Carlsson O, Rippe A, et al: Effect of acidity, glucose 20. Kato F, Mizukoshi S, Aoyama Y, et al: Immunosuppressive effects
of 3,4-Dideoxyglucosone-3-ene, an intermediate in the Maillarddegradation products and dialysis fluid buffer choice on peritoneal
solute and fluid transport in rats. Perit Dial Int 18:303–310, 1998 reaction. J Agric Food Chem 42:2068–2073, 1994
21. Schubert J, Sanders EB: Cytotoxic radiolysis products of irradi-9. Tuncer M, Sarikaya M, Sezer T, et al: Chemical peritonitis associ-
ated with high dialysate acetaldehyde concentrations. Nephrol Dial ated ,-unsaturated carbonyl sugars as the carbohydrates. Nat
New Biol 233:199–203, 1971Transplant 15:2037–2040, 2000
10. Inagi R, Miyata T, Yamamoto T, et al: Glucose degradation prod- 22. Simonsen O, Wieslander A, Landgren C, Rippe B: Less infusion
pain and elevated level of cancer antigen 125 by the use of a newuct methylglyoxal enhances the production of vascular endothelial
growth factor in peritoneal cells: Role in the functional and mor- and more biocompatible PD fluid. Adv Perit Dial 12:156–160, 1996
23. Rippe B, Simonsen O, Heimburger O, et al: Long-term clinicalphological alterations of peritoneal membranes in peritoneal dial-
ysis. FEBS Lett 463:260–264, 1999 effects of a peritoneal dialysis fluid with less glucose degradation
products. Kidney Int 59:348–357, 200111. Linden T, Forsba¨ck G, Deppisch R, et al: 3-deoxyglucosone, a
promoter of advanced glycation end products in fluids for perito- 24. Cappelli G, Bandiani G, Cancarini GC, et al: Low concentrations
of glucose degradation products in peritoneal dialysis fluids andneal dialysis. Perit Dial Int 18:290–293, 1998
12. Miyata T, Izuhara Y, Sakai H, Kurokawa K: Carbonyl stress: their impact on biocompatibility parameters: Prospective crossover
study with a three-compartment bag. Adv Perit Dial 15:238–242,Increased carbonyl modification of tissue and cellular proteins in
uremia. Perit Dial Int 19:23–26, 1999 1999
25. Kjellstrand P, Martinsson E, Wieslander A, et al: Degradation13. Schalkwijk CG, Posthuma N, ten Brink HJ, et al: Induction
of 1,2-dicarbonyl compounds, intermediates in the formation of in peritoneal dialysis fluids may be avoided by using low pH and
high glucose concentration. Perit Dial Int 21:338–344, 2001advanced glycation end-products, during heat-sterilization of glu-
cose-based peritoneal dialysis fluids. Perit Dial Int 19:325–333, 1999 26. Raj DSC, Choudhury D, Welbourne TC, Levi M: Advanced
glycation end products: A nephrologist’s perspective. Am J Kidney14. Miyata T, Kurokawa K, van Ypersele de Strihou C: Advanced
glycation and lipoxidation end products: Role of reactive carbonyl Dis 35:365–380, 2000
27. Weiss MF. Pathogenic role of advanced glycation end-productscompounds generated during carbohydrate and lipid metabolism.
J Am Soc Nephrol 11:1711–1752, 2000 (AGEs): An overview: Perit Dial Int 19(Suppl 2):47–52, 1999
28. Witowski J, Jo¨rres A: Glucose degradation products: Relationship15. Wieslander A, Linden T, Musi B, et al: Exogenous uptake of
carbonyl stress compounds promoting AGE formation from peri- with cell damage: Perit Dial Int 20(Suppl 2):31–36, 2000
29. Coles GA, Topley N: Long-term peritoneal membrane changes.toneal dialysis fluids, in Advanced Glycation End Products in Ne-
phrology, Contrib Nephrol (vol 131), edited by Da´ngelo A, Fa- Adv Ren Repl Ther 7:289–301, 2000
30. Ledl F, Schleicher E: New aspects of the Maillard reaction invaro S, Gambaro G, Basel, Karger, 2001, pp 82–89
16. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes foods and in the human body: Angew Chem Int Ed Engl 29:565–594,
1990JW: Alterations in nonenzymatic biochemistry in uremia: Origin
and significance of “carbonyl stress” in long term uremic complica- 31. Nursten HE: Recent development in studies of the Maillard reac-
tion. Food Chem 6:263–277, 1980-81tions. Kidney Int 55:389–399, 1999
